



DATE: December 20, 2005 SHEET 1_ of 1_

Form PTO-1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

ATTY. DOCKET NO.

6437.US.C4

SERIAL NO.

10/770,290

APPLICANT

Y. Qiu et al.

FILING DATE

February 2, 2004

GROUP

1615

U.S.PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	DOCUMENT NUMBER	PUBLI- CATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

/I.G./	A1	Dulac et al., "Bioequivalence of a New Sustained-Release Formulation of Sodium Valproate, Valproate Modified-Release Granules, Compared with Existing Sustained-Release Formulations After Once- or Twice-Daily Administration", Pharmacotherapy, 25 (1), 35-41, (2005)
/I.G./	A2	Roberts et al., "Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers", Biopharmaceutics & Drug Disposition, 17 (2), 175-182, (1996)

EXAMINER


/Isis Ghali/

DATE CONSIDERED

/Isis Ghali/

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)



Sheet 1 of 2

FORM PTO-1449 (Rev. 2032)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 6437.US.C4	Serial No. 10/770,290
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Qiu, et al.	
		Filing Date February 2, 2004	Group 1615

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date (if appro.)
/I.G./	4,369,172	01/18/83	Schor et al.			
	4,699,927	10/18/87	Deboeck			
	4,913,906	04/03/90	Friedman et al			
	4,988,731	01/29/91	Meade			
	5,009,897	04/23/91	Brinker et al			
	5,017,613	05/21/91	Aubert, et al.			
	5,019,398	05/28/91	Daste			
	5,055,306	10/08/91	Barry et al			
	5,169,642	12/08/92	Brinker et al			
	5,185,159	02/09/93	Aubert et al			
	5,212,326	05/18/93	Meade			
/I.G./	5,589,191	12/31/96	Ukigaya et al			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Name	Class	Subclass	Translation (Yes No)
/I.G./	94/27587	08.12.94	WO			
	00/37055	29.06.00	WO			
	00/45793 A1	08/10/00	WO			
	98/47491	29.10.98	WO			
	0 430 287 B2	06/05/91	EP			
/I.G./	0 141 267 B1	08/05/87	EP			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/I.G./		Bialer et al., Int. J. Pharmaceutics, 20: 53-63 (1984)
/I.G./		Bialer et al., Biopharmaceutics and Drug Disposition, 6: 401-411 (1985)
/I.G./		Bialer et al., Israel J. Med. Sci., 20: 46-49 (1984)
/I.G./		Collins et al., Extended Release Formulations of Anticonvulsant Medications Clinical Pharmacokinetics and Therapeutic Advantages, CNS Drugs 2000 Sept 14 (3): 203-212
/I.G./		Freitag, et al., "Depakote ER in Migraine Prophylaxis", Abstract No. S07.003, Neurology 54 April 2000 (Suppl 3), page A14.
/I.G./		Physicians' Desk Reference, (Web Version), 2001, Depakote ER, published by The Medical Economics Company
/I.G./		"Metabolism of Antiepileptic Drugs", 143-151, R.H. Levy, Ed. Raven Press, New York (1984)
/I.G./		Physicians' Desk Reference. 54 th Edition, 2000, Depakene Capsules, pp. 426-427, published by Medical Economic Company, Inc.
/I.G./		Physicians' Desk Reference. 54 th Edition, 2000, Depakote Tablets, pp. 431-437, published by Medical Economic Company, Inc.
/I.G./		Package insert for Depakote® ER dated August 2000
EXAMINER		DATE CONSIDERED
/Isis Ghali/		07/25/2007

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Rev. 2032)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 6437.US.C4	Serial No. 10770,290
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant Qiu, et al.	
(Use several sheets if necessary)		Filing Date	Group 1615

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date (if appro.)
/I.G./	5,593,690	01/18/83	Schor et al.			
/I.G./	5,593,694	01/14/97	Akiyama et al.			
/I.G./	5,980,913	11/09/99	Ayer et al.			
/I.G./	6,077,542	06/20/00	Sherman			
/I.G./	6,150,410	11/21/00	Engh, et al.			

FOREIGN PATENT DOCUMENTS

Document Number	Date	Name	Class	Subclass	Translation (Yes No)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/I.G./		Abstract of Collins, et al., "Extended Release Formulations of Anticonvulsant Medications Clinical Pharmacokinetics and Therapeutic Advantages", CNS Drugs, New Zealand, 2000, 14/3 (203-212)
/I.G./		Abstract of Bialer, et al., "Criteria to Assess in Vivo Performance and Bioequivalence of Generic Controlled-Release Formulations of Carbamazepine", Epilepsia, United States, 1998, 39/5 (513-519)
/I.G./		Abstract of Chun, et al., "Multiple-dose Evaluation of the Absorption Characteristics of Divalproex Sodium Tablets, a Delayed-Release Preparation of Valproate, in Healthy Volunteers", Clinical Drug Investigation, New Zealand, 1995, 10/1 (40-47)
/I.G./		Abstract of Bressolle, et al., "A Double Weibull Input Function Describes the Complex Absorption of Sustained-Release Oral Sodium Valproate", Journal of Pharmaceutical Sciences, United States, 1994, 83/10 (1461-1464)
/I.G./		Abstract of Hussein, et al., "Pharmacokinetics of Valproate after Multiple-dose Oral and Intravenous Infusion Administration: Gastrointestinal-related Diurnal Variation", Journal of Clinical Pharmacology, United States, 1994, 34/7 (754-759)
/I.G./		Abstract of Wilder, et al., "Gastrointestinal Tolerance of Divalproex Sodium", Neurology, United States, 1983, 33/6 (808-811)
/I.G./		Abstract of Wilder, et al., "Twice-daily Dosing of Valproate with Divalproex", Clinical Pharmacology and Therapeutics, United States, 1983, 34/4 (501-504)
/I.G./		Colins, et al., "Depakote CR: Biopharmaceutical and Pharmacokinetic Studies of a New Formulation for Once Daily Dosing", Neurology, Vol. 50(4), Supplement 4, April 1998, p. A426
/I.G./		Samara, et al., "Bioavailability of a Controlled-Release Formulation of Depakote", No. 3.053, Epilepsia, Vol. 38, Suppl. 8, 1997
/I.G./		Cavanaugh, et al., "Effect of Food on the Bioavailability of a Controlled-Release Formulation of Depakote Under Multiple-Dose Conditions", No. 2.002, Epilepsia, Vol. 38, Suppl. 8, 1997
EXAMINER /Isis Ghali/		DATE CONSIDERED 07/25/2007

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.